Repository logo
 
Publication

Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis

2024-07Journal article Open access
Simple item page
dc.contributor.authorEstarreja, João
dc.contributor.authorMendes, Priscila
dc.contributor.authorSilva, Carina
dc.contributor.authorCamacho, Pedro
dc.contributor.authorMateus, Vanessa
dc.date.accessioned2024-07-31T09:25:11Z
dc.date.available2024-07-31T09:25:11Z
dc.date.issued2024-07
dc.descriptionThis project was supported by FCT/MCTES UIDP/05608/2020, and UIDB/05608/2020.pt_PT
dc.description.abstractBackground: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of bevacizumab has been shown to be effective and has a lower cost, making it an interesting pharmacological approach; however, there is no consensus about its use. Therefore, this systematic review and meta-analysis aims to evaluate the efficacy, safety, and efficiency of bevacizumab in AMD patients. Methods: This review only focused on randomized controlled clinical trials published in 2010 in the MEDLINE database that compared the effect of bevacizumab with ranibizumab. The risk of bias in each included study was assessed using the CASP Randomised Clinical Trials checklist. Results: Twelve studies were included for qualitative synthesis, and nine of them were considered for meta-analysis. Bevacizumab-treated patients showed a significantly reduced neovascularization in a longer spectrum of time; however, they had a higher incidence of endophthalmitis than those treated with ranibizumab. Regarding efficiency, the mean number of administrations was reduced in the treatment with bevacizumab in comparison to ranibizumab. Conclusions: Clinical evidence demonstrates that bevacizumab has efficacy and safety profiles comparable with ranibizumab; however, it is relatively more efficient.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEstarreja J, Mendes P, Silva C, Camacho P, Mateus V. Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis. Pharmaceuticals. 2024;17(8):1000.pt_PT
dc.identifier.doi10.3390/ph17081000pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/17616
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/17/8/1000pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectOphthalmologypt_PT
dc.subjectAge-related macular degenerationpt_PT
dc.subjectAMDpt_PT
dc.subjectBevacizumabpt_PT
dc.subjectDrug therapypt_PT
dc.subjectnAMDpt_PT
dc.subjectNeovascular age-related macular degenerationpt_PT
dc.subjectWet macular degenerationpt_PT
dc.subjectFCT_UIDP/05608/2020pt_PT
dc.subjectFCT_UIDB/05608/2020pt_PT
dc.titleOff-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue8pt_PT
oaire.citation.startPage1000pt_PT
oaire.citation.titlePharmaceuticalspt_PT
oaire.citation.volume17pt_PT
person.familyNameEstarreja
person.familyNameRodrigues Gomes Mendes
person.familyNameSilva
person.familyNameCamacho
person.familyNamePinho Mateus
person.givenNameJoão
person.givenNamePriscila
person.givenNameCarina
person.givenNamePedro
person.givenNameVanessa Alexandra
person.identifier.ciencia-idEB19-EDA2-704B
person.identifier.ciencia-id6A16-5C18-F10B
person.identifier.ciencia-id2411-5936-0820
person.identifier.ciencia-id271F-B4E1-014E
person.identifier.ciencia-id5A12-571D-AD6A
person.identifier.orcid0000-0002-8283-3174
person.identifier.orcid0000-0002-0013-3140
person.identifier.orcid0000-0003-1021-7935
person.identifier.orcid0000-0002-2986-5652
person.identifier.orcid0000-0002-3204-3772
person.identifier.scopus-author-id55258764900
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationd16a20d0-ac73-4989-b83d-abeab53139f7
relation.isAuthorOfPublicationb02faa18-658e-4edc-b846-7c0b3646414c
relation.isAuthorOfPublication81a5cd80-1982-43ba-bde5-4c43ae0e5234
relation.isAuthorOfPublicationc41e9c52-157e-4375-8005-b609cfc374e7
relation.isAuthorOfPublication406041a5-682c-4f94-a4e2-ddbfc541313c
relation.isAuthorOfPublication.latestForDiscoveryc41e9c52-157e-4375-8005-b609cfc374e7

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration_a systematic review and meta-analysis.pdf
Size:
2.49 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos